Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

2.9K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.6K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.6K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.7K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

2.5K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.5K
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

6.9K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Design, regioselective, time gated synthesis of novel benzo[d]imidazole analogues as potential quorum sensing inhibitors targeting LasR in Pseudomonas aeruginosa.

Bioorganic chemistry·2026
Same author

Transport protein interaction and target pathway analysis of a hybrid antifungal compound synthesized by linking triazolothiadiazine ring system with the pyridine ring.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2025
Same author

Design, Synthesis, and 2D QSAR Analysis of Some Novel Pyrazolo[1,5-a]pyrimidine Derivatives as Pim-1 Kinase Inhibitors for the Treatment of MCF-7 Breast Cancer.

Drug development research·2025
Same author

Design, synthesis, and molecular dynamic simulations of some novel benzo[d]thiazoles with anti-virulence activity against Pseudomonas aeruginosa.

European journal of medicinal chemistry·2024
Same author

Theoretical study of the antioxidant mechanism and structure-activity relationships of 1,3,4-oxadiazol-2-ylthieno[2,3-d]pyrimidin-4-amine derivatives: a computational approach.

Frontiers in chemistry·2024
Same author

Avanafil: A comprehensive drug profile.

Profiles of drug substances, excipients, and related methodology·2024

Related Experiment Video

Updated: Mar 3, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.3K

Olmesartan.

Abdulrahman A Al-Majed1, Ahmed H H Bakheit2, Hatem A Abdel Aziz3

  • 1College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

Profiles of Drug Substances, Excipients, and Related Methodology
|April 23, 2017
PubMed
Summary
This summary is machine-generated.

Olmesartan, an angiotensin receptor blocker, effectively treats high blood pressure by relaxing blood vessels. This comprehensive profile details its properties, synthesis, analysis, and pharmacology for safe and effective use.

Keywords:
AssayOlmesartanPharmacokineticsPhysical characteristicsSpectral propertiesStabilitySynthesisUses

More Related Videos

Investigation of Xenobiotics Metabolism In Salix alba Leaves via Mass Spectrometry Imaging
09:21

Investigation of Xenobiotics Metabolism In Salix alba Leaves via Mass Spectrometry Imaging

Published on: June 15, 2020

3.6K
Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
08:15

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

20.1K

Related Experiment Videos

Last Updated: Mar 3, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.3K
Investigation of Xenobiotics Metabolism In Salix alba Leaves via Mass Spectrometry Imaging
09:21

Investigation of Xenobiotics Metabolism In Salix alba Leaves via Mass Spectrometry Imaging

Published on: June 15, 2020

3.6K
Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
08:15

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

20.1K

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Drug Development

Background:

  • Olmesartan is an angiotensin receptor blocker used to treat hypertension.
  • It functions by relaxing blood vessels, facilitating easier blood flow.
  • It can be administered as a standalone treatment or in conjunction with other antihypertensive medications.

Purpose of the Study:

  • To provide a comprehensive profile of olmesartan.
  • To detail its nomenclature, formulae, elemental analysis, and physical appearance.
  • To describe synthesis methods, usage, physicochemical properties, and analytical procedures.

Main Methods:

  • Physicochemical characterization including pKa, solubility, X-ray powder diffraction, and melting point.
  • Analysis using compendial, spectroscopic, electrochemical, and chromatographic techniques.
  • Pharmacological evaluation including actions, therapeutic uses, interactions, and adverse effects.

Main Results:

  • Detailed information on olmesartan's chemical and physical properties is presented.
  • Various synthesis routes and analytical methods are described.
  • Comprehensive pharmacological data, including therapeutic applications and safety profiles, is provided.

Conclusions:

  • Olmesartan is a well-characterized antihypertensive agent.
  • The profile offers valuable data for researchers and clinicians.
  • Extensive references support the presented findings on olmesartan.